Shares of Scholar Rock surged +13.5% to $62.91 after the FDA cleared Isembyld, its muscle-strengthening treatment for spinal muscular atrophy, vaulting the stock to a new three-year high and transforming the company from a cash-burning lab into a real drugmaker overnight. For a firm that has never booked a dollar of revenue, the stakes around execution are enormous.
• The First Drug Approval Ends a Bumpy Road to Market. Isembyld is approved for adults and children aged two and older with SMA who are already on existing genetic therapies — making it the first muscle-targeted treatment in the category. This milestone nearly didn't happen on time: manufacturing delays at a contract facility — unrelated to drug safety — created real approval risk.
Scholar Rock resubmitted its application after aligning with the FDA and adding a second U.S.-based manufacturing site to strengthen its supply chain. The approval came weeks ahead of its September 30 deadline.
• Wall Street Sees a Blockbuster, But Revenue Is Still Theoretical. Bank of America models $2 billion in risk-adjusted peak sales , while other firms have set estimates ranging up to $1.5 billion. Yet the company currently sits at $0 in revenue and -$0.84 earnings per share last quarter.
Its net loss widened to $105.5 million in Q1 2026 , and it held roughly $492 million in cash — a runway that must now fund a full commercial launch. The gap between analyst projections and today's bank balance is where shareholder risk lives.
• The SMA Market Is Large But Competitive. Approximately 25,000 Americans live with SMA , and the broader treatment market was valued at $7.3 billion in 2023, growing at roughly 19% annually. Isembyld doesn't replace existing therapies — it layers on top of them — so payer negotiations around pricing will determine how much of that market Scholar Rock captures. Existing SMA drugs like Spinraza already cost $375,000 per year for maintenance , raising questions about insurer willingness to add another expensive therapy.
• The Pipeline Offers Upside Beyond SMA — If It Works. Scholar Rock is testing the same drug in a separate muscle-wasting condition called FSHD, affecting about 30,000 people in the U.S. and Europe, with a mid-stage trial underway.
The FDA recently granted that program Fast Track and Orphan Drug status , which could accelerate a future second approval. Success there would meaningfully expand the revenue ceiling; failure would leave the company a one-drug story trading at roughly $7 billion in market value on zero sales.